NCT06058988 - Trastuzumab Deruxtecan (T-DXd) for People With Brain Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 22, 2023

Primary Completion Date

September 22, 2027

Study Completion Date

September 22, 2027

Conditions

Brain CancerGlioblastomaMetastatic CancerLeptomeningeal MetastasisRecurrent Glioblastoma

Interventions

DRUG

Trastuzumab deruxtecan

All participants will receive T-DXd prior to indicated brain tumor resection/biopsy

Trial Locations (1)

RECRUITING

Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York